Table 2 Patient characteristics of LCRC and RCRC
| Â | Total | RCRC | LCRC | Â |
|---|---|---|---|---|
| Â | N (%) | N (%) | N (%) | P value |
Patient Number | 901 (100.0) | 136 (100.0) | 765 (100.0) | Â |
Gender | ||||
 Male | 557 (61.8) | 74 (54.4) | 483 (63.1) | .0536 |
 Female | 344 (38.2) | 62 (45.6) | 282 (36.9) |  |
Mean age at treatment (years) | ||||
 Mean (SD) | 59.95 (12.02) | 61.39 (11.91) | 59.70 (12.02) | .0992 |
 Median (min, max) | 60 (22, 96) | 61 (22, 96) | 60 (26, 90) |  |
Age group (years) | ||||
<50 | 163 (18.1) | 18 (13.2) | 145 (19.0) | .2256 |
50-64 | 420 (46.6) | 64 (47.1) | 356 (46.5) | Â |
65+ | 318 (35.3) | 54 (39.7) | 264 (34.5) | Â |
Histology | ||||
 Mucinous adenocarcinoma | 36 (4.0) | 15 (11.0) | 21 (2.7) | < .0001 |
 Non-mucinous adenocarcinoma | 836 (92.8) | 115 (84.6) | 721 (94.2) |  |
 Others | 29 (3.2) | 6 (4.4) | 23 (3.0) |  |
Grade | ||||
 1 | 43 (4.8) | 5 (3.7) | 38 (5.0) | .0002 |
 2 | 689 (76.5) | 90 (66.2) | 599 (78.3) |  |
 3 | 93 (10.3) | 28 (20.6) | 65 (8.5) |  |
Undifferentiated or Unknown | 76 (8.4) | 13 (9.6) | 63 (8.2) | Â |
Stage at diagnosisa | ||||
 I-III | 396 (44.0) | 64 (47.1) | 332 (43.4) | .4281 |
 IV | 505 (56.0) | 72 (52.9) | 433 (56.6) |  |
Cetuximab combination with chemotherapy | 893 (99.1) | 135 (99.3) | 758 (99.1) | Â |
Chemotherapy after end of cetuximab | 495 (54.9) | 61 (44.9) | 434 (56.7) | Â |
Death | 747 (82.9) | 121 (89.0) | 626 (81.8) | Â |
Follow-up (months) | ||||
 Mean (SD) | 13.0 (8.6) | 10.1 (8.0) | 13.5 (8.6) |  |
 Median (min, max) | 11.5 (0.1, 39.4) | 8.1 (1.2, 34.8) | 12.5 (0.1, 39.4) |  |